Fecal Calprotectin in Patients Infected with Intestinal Protozoan Infections
Launched by SOHAG UNIVERSITY · Mar 17, 2025
Trial Information
Current as of April 30, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to understand how a substance called fecal calprotectin, found in stool samples, relates to certain intestinal infections caused by two types of protozoa: Blastocystis hominis and Entamoeba histolytica. Researchers want to see if levels of fecal calprotectin can help identify inflammation in the intestines of patients who have these infections compared to those who do not have them. The trial will collect a total of 120 stool samples from three groups: patients with gastrointestinal issues who have these infections, patients with gastrointestinal issues who do not have any protozoal infections, and healthy volunteers without any gastrointestinal problems.
To be eligible for this trial, participants should be experiencing gastrointestinal symptoms and either be infected with one of the two protozoa or be free of any infections. It's important that participants have not taken any antiparasitic or antibiotic medications in the two weeks before providing their stool samples. This study is not yet recruiting participants, but if you fit the criteria, you could help researchers gain valuable insights into how fecal calprotectin levels relate to these infections, which could lead to better diagnosis and treatment options in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- 120 fecal samples will be collected as the following:
- • 40 samples from patients complaining of gastrointestinal manifestations and only infected with B.hominis and E.histolytica.
- • 40 samples from patients complaining of gastrointestinal manifestations without any protozoal infection.
- • 40 healthy control cross-matched volunteers (without gastrointestinal manifestations, or intestinal parasites).
- Exclusion Criteria:
- • persons received antiparasitic drugs or antibiotic 2 weeks before sample collection Patients with mixed intestinal protozoa Patients with intestinal protozoa rather than Entamoeba histolytica and Blastocystis
About Sohag University
Sohag University is a distinguished academic institution located in Sohag, Egypt, committed to advancing healthcare through rigorous clinical research. As a clinical trial sponsor, the university leverages its robust infrastructure and multidisciplinary expertise to facilitate innovative studies aimed at improving patient outcomes and contributing to the global body of medical knowledge. With a focus on ethical standards and scientific integrity, Sohag University collaborates with healthcare professionals and researchers to conduct trials that address critical health issues, ensuring the advancement of evidence-based practices in the healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sohag, , Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported